Jiangxi Fushine Pharmaceutical Co., Ltd. (SHE:300497)

China flag China · Delayed Price · Currency is CNY
18.32
-0.64 (-3.38%)
Jul 10, 2026, 3:04 PM CST
Market Cap9.87B +98.3%
Revenue (ttm)1.31B +22.2%
Net Income3.93M
EPS0.01
Shares Out 538.65M
PE Ratio2,510.21
Forward PE14.20
Dividendn/a
Ex-Dividend Daten/a
Volume34,882,068
Open23.00
Previous Close18.96
Day's Range18.28 - 23.00
52-Week Range9.01 - 24.18
Beta0.23
Analystsn/a
Price Targetn/a
Earnings DateAug 12, 2026

About SHE:300497

Jiangxi Fushine Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of APIs and pharmaceutical intermediates in China and internationally. The company offers β-lactamase inhibitors, carbapenem antibiotics, and antiviral drug intermediates; argatroban injection for the treatment of acute ischemic stroke; and doxycycline hydrochloride dispersible tablets to treat rickettsial diseases, mycoplasmal and chlamydial infections, relapsing fever, brucellosis, cholera, tularemia, plague, an... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2002
Employees 1,663
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 300497
Full Company Profile

Financial Performance

In 2025, SHE:300497's revenue was 1.18 billion, an increase of 0.61% compared to the previous year's 1.18 billion. Losses were -55.03 million, -79.78% less than in 2024.

Financial Statements